How much funding has Quentis Therapeutics raised?

Quentis Therapeutics has raised $48.0M in total funding, most recently a Series A round.

Who are Quentis Therapeutics's investors?

Quentis Therapeutics's investors include Jerel Davis, Polaris Partners.

Where is Quentis Therapeutics headquartered?

Quentis Therapeutics is headquartered in New York, United States.

What industry is Quentis Therapeutics in?

Quentis Therapeutics operates in Biotech, Healthcare.

Quentis Therapeutics

New York, United States · $48.0M raised

Biotech

Healthcare

Headquarters: New York
Business Model: B2B
Website: quentistx.com

Total Funding: $48.0M
Last Round: $48.0M Series AJan 2018
Rounds: 1

About

Quentis Therapeutics is a preclinical stage biotechnology company translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, Quentis is pioneering first-in-class ER stress response modulators to boost the immune system's ability to fight cancer, with its lead program a first-in-class IRE1α inhibitor.

Summary

Quentis Therapeutics is a Biotech company based in New York, United States. It has raised $48.0M in total across 1 round, most recently a $48.0M Series A round in Jan 2018. Investors include Jerel Davis and Polaris Partners.

X (Twitter)